Market Snapshot
S&P Futures
3,914.75
Dow Futures
31,478
Nasdaq Futures
12,132.75
Avadel Pharmaceuticals plc (AVDL) stock rallied over 3.40% intraday to trade at $2.43 a share on NASDAQ. The stock opened with a gain of 0.83% at $2.39 and touched an intraday high of $2.44, rising 3.40% against the last close of $2.35. The stock went to a low of $2.28 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-06-23 | $2.39 | $2.44 | $2.28 | $2.43 | 544,500 |
2022-06-22 | $2.41 | $2.48 | $2.34 | $2.35 | 398,100 |
2022-06-21 | $2.38 | $2.53 | $2.36 | $2.46 | 612,100 |
2022-06-17 | $2.35 | $2.5 | $2.31 | $2.34 | 1,040,400 |
2022-06-16 | $2.27 | $2.31 | $2.2 | $2.3 | 408,800 |
2022-06-15 | $2.23 | $2.41 | $2.23 | $2.31 | 950,000 |
2022-06-14 | $2.25 | $2.28 | $2.12 | $2.2 | 778,500 |
2022-06-13 | $2.31 | $2.31 | $2.12 | $2.25 | 964,600 |
2022-06-10 | $2.33 | $2.43 | $2.3 | $2.43 | 757,000 |
2022-06-09 | $2.61 | $2.63 | $2.34 | $2.36 | 844,400 |
Employees-
Beta1.02
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryPharmaceuticals
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) stock price is $2.43 as of the last check on Thursday, June 23. During the trading session, AVDL stock reached the peak price of $2.44 while $2.28 was the lowest point it dropped to.
The NASDAQ listed AVDL is part of Pharmaceuticals industry that operates in the broader Health Care sector. Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy.
Mr. Gregory J. Divis Jr.
CEO & Director
Mr. Thomas S. McHugh
Sr. VP & CFO
Dr. Jordan S. Dubow M.D.
Consultant
Mr. Gregory J. Davis
VP of Corp. and Bus. Devel.
AVDL stock traded closed the last session at $2.43, which is $0.08 or 3.40% lower than its previous close of $2.35. AVDL's current trading price is 131.43% lower than its 52-week high of $11.59 where as its distance from 52-week low of 1.05% is -79.03%.
Number of AVDL employees currently stands at -. AVDL operates from 10 Earlsfort Terrace, Dublin 2, Ireland.
Official Webiste of $AVDL is: https://www.avadel.com
AVDL could be contacted at AVDL operates from 10 Earlsfort Terrace, Dublin 2, Ireland, or at phone #353 1 901 5201 and can also be accessed through its website.
AVDL stock volume for the day was 544,463 shares while in the previous session number of AVDL shares traded was 544,500 . The average number of AVDL shares traded daily for last 3 months was 3.91 Million.
The percentage change in AVDL stock occurred in the recent session was 3.40% while the dollar amount for the price change in AVDL stock was $0.08.
In the recent session, the day high for AVDL stock was $2.44 while the low for AVDL stock touched on the day was $2.28.
The market value of AVDL currently stands at 141.01 Million with its latest stock price at $2.43 and 58.82 Million of its shares outstanding.